Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia
about
Drug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs.Kinetic target-guided synthesis in drug discovery and chemical biology: a comprehensive facts and figures surveyA genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug targetAntipurinergic therapy corrects the autism-like features in the poly(IC) mouse modelMaximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia.Intracranial self-stimulation to evaluate abuse potential of drugs.The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.Development of allosteric modulators of GPCRs for treatment of CNS disordersThe NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis.Inhibition of cholinergic pathways in Drosophila melanogaster by α-conotoxins.Axon targeting of the alpha 7 nicotinic receptor in developing hippocampal neurons by Gprin1 regulates growth.Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophreniaXanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.Investigational dopamine antagonists for the treatment of schizophrenia.Neural circuitry and immunity.State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effectsGalantamine effect on tularemia pathogenesis in a BALB/c mouse model.Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in MiceCholinergic connectivity: it's implications for psychiatric disorders.Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerCholinergic neurons excite cortically projecting basal forebrain GABAergic neurons.Chromosome conformation elucidates regulatory relationships in developing human brain.Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.Use of allosteric targets in the discovery of safer drugs.Nicotinic modulation of intrinsic brain networks in schizophrenia.Leading compounds for the validation of animal models of psychopathology.Muscarinic acetylcholine receptors: novel opportunities for drug development.Emerging drugs for schizophrenia: an update.Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine coreThe therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.Cognitive impairment in schizophrenia: the great unmet need.Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.
P2860
Q27693888-8DCF9A3C-A561-4AE7-A833-5281DF0DE5D2Q28072198-2528916A-2883-431C-95A7-364595B3C267Q28487183-07B96671-59C4-40D2-A5E2-6C6262D036B0Q28487975-8B8A2676-954C-43BB-A10D-EE02971D41E1Q30381001-A344073F-AA6B-4047-8147-53B4B4453E48Q30406145-0CFB23B9-2968-42FA-9F1C-44A520CA8620Q30410518-00C5DBA0-8AF1-49CD-85CB-2E467FCBBB06Q33624417-034E3298-412A-4818-9077-B577B06F36D2Q33845750-C95F6819-F6E7-4421-9A8A-D51C45C349C3Q33920257-0708F45C-A97E-4932-80BE-073387F91EDCQ34373958-760B6A2A-C77C-4569-827F-CBF6E1CF466DQ34455707-81DD71FC-C265-49AC-9C65-EEE395CC21F4Q34580443-4D3413AF-BD24-4B08-84D6-978D14C07265Q34613107-D59EEADF-8B0B-4A10-84CC-531C6D23D956Q35576500-95378DB5-7B46-423C-A478-81F0902753E6Q35834299-4E3941CF-833B-440D-9222-BAFB5788730CQ36174107-31245F6C-D103-46DC-BF88-0903919D9707Q36219281-32AA1A4B-F5A4-49C0-AD8D-F828EEF3F7DAQ36356306-168EFFDA-0615-4F4F-893C-F775111F2694Q36551920-C7B919BF-1857-4B65-B59A-8CBABF7E0BBCQ36732752-4C6D53AB-339A-4BDA-98C8-75D79C9C444BQ36777164-3E0793F8-9D8F-4386-9EF9-31A3771D6C1BQ36794968-2251C3F6-DA34-4153-AD98-8CE61253C66FQ36812599-65D103B9-7B65-4484-975E-9C6C9B2C1A7FQ37067455-5663B6E3-F331-4E74-9C62-B19F62D96BD0Q37258840-127E5630-F01D-40B9-A73B-EAC033833F24Q37597240-7BB49636-3A1A-4DC3-B551-7F2595D3ED8AQ37712138-ABB4C8B2-2D71-4D31-86D9-F36D21429E92Q38070176-D1A66E26-C789-4D63-9C17-B58A11357AF1Q38109800-D6366536-D145-47F6-8D0D-DC2100ECD2CCQ38116676-EBE0C46A-6777-43B4-A4C5-9C9DB9133F85Q38128733-6451B2E1-2247-480F-813D-6C59FD81F27BQ38218059-4D357707-D851-4845-AAD5-C97BECE95E6CQ38252404-B1AD23F3-B762-4F7B-A924-F66F5A5803E8Q38268878-208C6323-5B50-45A7-8C20-189AFFDC32ACQ38436762-13E88964-3173-4AEA-A2F3-53ABC458F1D6Q38437959-092A972B-C551-4B0B-8FB3-0A1691AE1547Q38560778-82AD096A-E413-421E-A322-69821D7D700AQ38673548-78B422FE-7C10-4A9F-8D0D-F001CDDE6393Q38699013-8BD33E8A-9E85-4820-9C1C-B934FFF20423
P2860
Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Muscarinic and nicotinic acety ...... the treatment of schizophrenia
@ast
Muscarinic and nicotinic acety ...... the treatment of schizophrenia
@en
type
label
Muscarinic and nicotinic acety ...... the treatment of schizophrenia
@ast
Muscarinic and nicotinic acety ...... the treatment of schizophrenia
@en
prefLabel
Muscarinic and nicotinic acety ...... the treatment of schizophrenia
@ast
Muscarinic and nicotinic acety ...... the treatment of schizophrenia
@en
P2093
P2860
P356
P1476
Muscarinic and nicotinic acety ...... the treatment of schizophrenia
@en
P2093
Carrie K Jones
Michael Bubser
Nellie Byun
P2860
P2888
P356
10.1038/NPP.2011.199
P407
P577
2011-09-28T00:00:00Z
P5875
P6179
1016959373